DNA Nanoparticle Micelles for Ocular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ocular drug delivery methods, such as eye drops, face significant challenges due to low bioavailability and rapid clearance from the eye, leading to poor compliance and frequent administration, while invasive alternatives like implants cause side effects and surgical risks.
Innovation Solution
The development of drug-loaded micelles comprising self-assembled amphiphilic biopolymers, specifically DNA nanoparticles with hydrophobic modifications, which increase drug adherence time on the eye, allowing for lower frequency of administration and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eye drops are used for ocular drug delivery, then the treatment can be administered topically, but the drug bioavailability is less than 5% in anterior segment and less than 0.05% in posterior segment due to rapid clearance and poor permeability
Solution Approach 1:
The patent introduces polymeric micelles as intermediary carriers that mediate drug delivery to ocular tissues. These micelles protect the drug from rapid clearance by tear drainage and blinking, while facilitating enhanced permeability across corneal and conjunctival barriers through their unique structure and interaction with ocular surfaces.
Solution Approach 2:
The patent modifies the physical and chemical parameters of drug delivery by using polymeric micelles with specific size ranges (20-200 nm), hydrophilic-hydrophobic balance, and surface properties that optimize residence time on ocular surfaces and enhance cellular uptake, thereby improving bioavailability from less than 5% to significantly higher levels.
2Reliability
If highly concentrated eye drops are administered frequently to maintain therapeutic concentration, then the drug efficacy can be maintained, but patient compliance drops to approximately 60% and severe side effects occur including anaphylactic shocks
Solution Approach 1:
The polymeric micelles provide continuous drug release at the ocular site, maintaining therapeutic concentrations over extended periods. This sustained release mechanism eliminates the need for frequent dosing, transforming the discontinuous administration pattern into a continuous therapeutic action that improves compliance while maintaining efficacy.
Solution Approach 2:
The micellar system allows the drug to rapidly penetrate ocular barriers and achieve therapeutic concentrations quickly, then maintains these levels through sustained release. This 'rush through' the barriers followed by prolonged presence reduces the frequency of administration from multiple times daily to less frequent dosing.
3Duration of action of moving object
If viscosity and composition of eye drops are increased to improve effectiveness, then drug retention time increases slightly, but vision is reduced when medicine is applied leading to lack of compliance
Solution Approach 1:
The polymeric micelles act as flexible nanoscale carriers that can adhere to ocular surfaces without forming thick viscous layers. Their small size and surface-adhering properties allow them to retain drug at the site of action while remaining optically transparent, unlike conventional viscous eye drops that scatter light and reduce vision.
4Reliability
If invasive drug depots like punctual plugs and implants are used to replace eye drops, then drug delivery effectiveness can be improved, but surgical interventions are required and allergic reactions, spontaneous ejection, and intraocular infections occur
Solution Approach 1:
The polymeric micelles function as temporary, disposable delivery vehicles that are administered topically and naturally clear or degrade after delivering their payload. Unlike permanent implants requiring surgical removal, these micelles complete their function and are eliminated without intervention, avoiding surgical risks and long-term foreign body complications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances drug adherence and bioavailability, reducing the need for frequent dosing, minimizing side effects, and enabling the use of previously harmful medications, thereby improving treatment compliance and efficacy.
Implementation Method 1
modularly assembled nano-objects in the form of drug-loaded micelles comprising self-assembled amphiphilic biopolymers
Implementation Method 2
self-assembled amphiphilic biopolymers
Implementation Method 3
these goals could be met by modularly assembled nano-objects in the form of drug-loaded micelles comprising self-assembled amphiphilic biopolymers... we are able to significantly increase the adherence time of the drug in the eye
Data Source
AI summary
The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.